Randomisation Program

Call Freefone 0800 138 5451 to contact the RECOVERY team for URGENT problems using the Randomisation Program or for medical advice. All NON-URGENT queries should be emailed to recoverytrial@ndph.ox.ac.uk

	Secti
Treating clinician	Date a
A1. Name of treating clinician	
Patient details A2. Patient surname	
Patient forename	
A3. NHS number	☐ Tick if not available
A4. What is the patient's date of birth?	01 V / January V / 2000 V Age: 21y 6m
A5. What is the patient's sex? Inclusion criteria	~
A6. Has consent been taken in line with the protocol? If answer is No patient cannot be enrolled in the study	~
A6.0 How was consent obtained?	·
A6.1 Has consent been given for the early phase assessment of dimethyl fumarate?	Yes V
A6.2 Has S/F ₉₄ been measured according to the SOP?	Yes ▼
A7. Does the patient have proven or suspected SARS-CoV-	
2 infection? If answer is No patient cannot be enrolled in the study	
A8. Does the patient have any medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial?	~
A9. COVID-19 symptom onset date:	V/ V/ V
A10. Date of hospitalisation:	
A11. Does the patient require oxygen?	
A12. Please select one of the following to describe the	
current level of ventilation support	
A12.1 Enter latest oxygen saturation measurement (%) A12.2 Enter latest CRP measurement since admission to	☐ ☐ Tick if not measured
A12.2 Enter latest CRP measurement since admission to hospital (mg/L) Enter 0 if below the limit of measurement	☐Tick if not measured ☐Tick if greater than limit of measurement
A12.3 Enter latest creatinine measurement since admission to hospital	μmol/L ▼ □ Tick if not measured
A12.4 Enter latest D-dimer measurement since admission	ng/mL ▼ □Tick if not measured
to hospital Enter 0 if below the limit of measurement	Tick if greater than limit of measurement
A12.5 Has the patient received a COVID-19 vaccine? Does the patient have any CURRENT comorbidities or or the patient have any CURRENT comorbidities or the pati	v
A13.1 Diabetes	other medical problems or treatments?
A13.2 Heart disease	
A13.3 Chronic lung disease	
A13.4 Tuberculosis	
A13.5 HIV	
A13.6 Severe liver disease	
A13.7 Severe kidney impairment (eGFR<30 or on dialysis)	
A13.8 Known long QT syndrome	~
A13.9 Current treatment with macrolide antibiotics	
Which are to continue Macrolide antibiotics include clarithromycin, azithromycin and erythromycin	
A13.10 Antiplatelet therapy	~
Includes aspirin, clopidogrel, ticagrelor, prasugrel, dipyridamole	
A13.12 Has received tocilizumab therapy during this admission	~
Are the following treatments UNSUITABLE for the parties of the par	
A14.1 Dimethyl fumarate NB Dimethyl fumarate is NOT suitable if patient is pregnant or breastfeeding	No v
A14D.1 Baricitinib	V
NB Baricitinib is NOT suitable if patient (i) is pregnant; (ii) has eGFR <15 ml/min or is on dialysis/haemofiltration; (iii) has	
active TB; or (iv) has neutrophil count <0.5 A14F.1 Empagliflozin	~
Empagliflozin is NOT suitable if patient (i) has type 1 diabetes mellitus; or (ii) is pregnant or breastfeeding	
Are the following treatments available? A15.1 Dimethyl fumarate	Yes ✓
A15D.1 Baricitinib	res V
A15F.1 Empagliflozin	
Current medication	
A16.1 Is the patient currently prescribed remdesivir?	~
A16.2 Is the patient currently prescribed systemic corticosteroids (dexamethasone, prednisolone, hydrocortisone, methylprednisolone)?	~
Please do not include topical or inhaled treatments	
A16.4 Is the patient currently on warfarin or a direct oral anticoagulant? Includes apixaban, rivaroxaban	~
Includes apixaban, rivaroxaban A16.5 What venous thromboembolism prophylaxis is the	~
patient receiving? Standard = usual for hospitalised patients (not increased due to	
COVID-19); Higher dose = treatment dose or increased prophylaxis due to COVID-19	
A17.2.1 Oxygen delivery mode	v
A17.2.2 Inspired oxygen concentration (FiO ₂) (%)	
A17.2.3 High-flow nasal oxygen flow rate	
A17.2.4 Peak end-expiratory pressure (PEEP) (cm H ₂ 0)	
A17.2.5 Peripheral oxygen saturation (SpO ₂) (%)	
A17.2.6 Respiratory rate (breaths per minute)	
Please sign off this form once complete Surname:	
Forename:	
Professional email:	
	Continue
	Cancel